| Website | glycovaxyn.com |
| Category | BioTech |
| Phone | +41 44 733 85 85 |
| Employees | |
| Description | bioconjugate vaccines |
| Total | $22.1M |
| Unattributed, 7/06 Index Ventures Sofinnova Partners | $817k |
| Series B, 3/09 Edmond de Rothschild Venture Capital Index Ventures Sofinnova Partners | $21.3M |
GlycoVaxyn has built a broad portfolio of conjugate vaccines against common severe bacterial infections based on its unique, proprietary invivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the difficulties involved in current methods. The lead conjugate vaccines in development are directed against Shigella dysenteriae, to prevent serious intestinal infections, and against hospital acquired Staphylococcus aureus. GlycoVaxyn also has active programs against N. meningitidis and Group A Streptococcus. GlycoVaxyn, a spinout of the Swiss Federal Institute of Technology (ETH), is based in Schlieren, near Zurich, Switzerland.
